ADAP - Earnings call transcript Q2 2019 | Adaptimmune Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Second Quarter of 2019 Adaptimmune Earnings Conference Call. My name is Carla, and I will be your conference operator today. [Operator instructions] And now I would like to turn the call over to Juli Miller. Go ahead, please.

Juli Miller

Good morning, and welcome to Adaptimmune's conference call to discuss our second-quarter 2019 financial results and other business update. releases please morning, of review statements press ask I our two there. to you the issued earlier and this would forward-looking We full text

and with our making brief me Executive named call. and a to are portion. Officer; the Officer President our Adaptimmune's prepared Chief be with factors, this in incoming of Development our Chief during Research we co-Founder; the of a for Bill outlined of could will CEO; anticipate Adrian prepared Officer Operating those Amado, available latest portion As this and materially Rawcliffe, recently reminder, and Supply number our call Lunger, John Officer; Chief and for our Patient Chief the our actual including Bertrand, Q&A Helen due SEC. results differ Tayton-Martin, Noble, projections Rafael Business filings after James

James With over turn to call James? that, the Noble. I'll

James Noble

joining you, of Julie. treating they what XX an and good and have my morning, in will I've everyone, Thank am convinced you I in And receptors, will important quarterly field for the patients. CEO. Adaptimmune us years role be spent as for T-cell last call that for thank

depth have compelling durability sarcoma data the have next-generation We seen of already a with recently ADP-AXMX responses. trial T-cell a and in radiation combination improve low-dose to and and started SPEAR the with trial with

over know The tasks And to turn It's Adrian? commercialization. over its my that, energy he I the he will evolution and through I will handing across the Adrian. plans company. future introducing taking do with as bring is execution that Adrian. and to job the next focus be pleasure to changes accelerating the in an ahead, now company the final to CEO will that excellent toward it already for

Adrian Rawcliffe

of the personally me I'll Thank in more a start executive month's little the I areas a share leadership rest for transition. the about the support and and the of your be you, during months. want And your three you After I on coming company the James. transition, thank to focusing to of since want team that

First, focus our increasing execution. to I on want continue rapid

had always potential of a pipeline T-cells. SPEAR always we've high and had great We've science,

need execution bring to patients rapid of our to focus to we cancer However, and on to benefit this with shareholders.

this we've You trial, started May, already. the have low-dose may trial the clinical in noticed and increased update the the SPEARHEAD-X pace sub-study. SURPASS radiation Since

initial our first with first T-cell And first The is SPEARHEAD-X trial The announced program. SURPASS three sub-study next These AFP the May our readouts data and tumors. trial trials in trial. late-stage year were SURPASS initial is the our initiated started we'll ADP-AXMX next-generation is to update, ongoing we've trial sub-study radiation and low-dose have the data in our with trial into only radiation at along of improve sarcoma trial. the traffic

expect the completed have by futility our analysis We in trial also to SPEARHEAD-X then.

trial, wrap by ADP-AXMXX lung execution means do. that and where the triple rapid won't the we've clear indications of we what both made across about on this Focusing have into expression of and tumor the the MAGE-AX the to overlapping MAGE-AXX decision MAGE-AXX trials, we end being the XXXX. tested Feeding MAGE-AXX all also higher seems indications up was And expression. decision than and that MAGE-AX fact express the

on MAGE-AX. So it for sense makes us focus to

of improve recruitment, trials clinical you'll stage in forward, improved to treatments. insights convert see early our to enhance changes the designed translational into pace particularly Looking to and ability

including the of at building today the the to such SPEARHEAD-X be of rapid company expertise readiness and the announced of on to Vineti product the products starts to things with our build to launch implementations deliver ready XXXX. as This want first our trial, in I Secondly, commercial obviously software scale. delivery

Lunger and John has Chief been Supply of of Chain view as to our and responsible direction. of deliver our been this and Supply should scale John He Manufacturing products strong the Officer has intent SVP Patient operations. creation promotion stages. of statement with in the a patients and You now members we lead capabilities build development leadership the Adaptimmune's of supply need the clinical commercial other our will CMC integrated for manufacturing for and the to to

This near-term and integrated want Finally, and expertise I TCRs this across the to more world-class apply applicable manufacturing broadly. research, the most is driving development year. cell built believe process stem manufacturing giving forward which T-cells. in this and is update field. ASGCT our cell-derived allogeneic The program and and at to these course. the which development move to all including advanced allogeneic both this an leverage A capabilities supply progressing CAR-T therapy example look we've includes across program, We we to and in among T-cells, includes apace, continues we due updates you for of the provided

strategy of months. over the coming our details course of the will more plans I and provide

this President on We Rafael Amado, of company XX. be the will also leaving announced R&D, our morning that August

aim expertise We where he his today, embarking market SPEAR being are first Rafael us development and to we T-cell clinical have on and XXXX. great to his the of to that a our get team everything in therapy with for of debt have on done the late-stage

a and the And Rafael over actually, I'd to like the the Rafael? update. call time turn me, first last so for clinical for to for time,

Rafael Amado

Thank for you, us. Ad, joining everyone, and thanks,

these last As Ad new over the the said, of with progress have three trials. start we month great made

SPEAR best focus solid infiltrate how research to on enable addition, understanding induce we learn aim our to continue from and and cytotoxicity. gaining expand, We're tumors our every to patient. of In greater T-cells translational to a

that about SPEAR make new other think implementing our We're tissue response that factors and T-cells after of in also we treatment. We're approaches are T-cells, we markers may effective. influence target learning with and along about more expression SPEAR before tumor learning

we further to about learn based of allogenic the enhancements, technologies investigate Likewise, on findings, products. new and will continue continue of our sources, translational evaluate as lymphodepletion will to such SPEAR we safety improve T-cells based to our We regimens our these data. on and

prolonged Since cancer our serious one of update These May, of two one in who occurred and been and received reports lung pancytopenia. severe events event have with in in lymphodepletion patient cycles there Both patients two patient who ADP-AXMXX, single was that of related ADP-AXMX. a Sarcoma pancytopenia. ADP-AXMX. subsequently of to patient received by these X of complications prolonged died Grade neurotoxicity with followed cycle lymphodepletion additional had One probably adverse

that that X.X and per for All grams a believe per believe for days. to cyclophosphamide. day regimen include depletion as the meter the died patient milligrams of part of regimen, SAEs. two eligibility first XX higher in amended therapy. unrelated of likely to square reversion of dose contributed have previously dose criteria T-cell two the used risk preconditioning which received been The square to further per prolonged SPEAR of stroke high mitigate trials subsequently the to per To day and we of the patients patients, meter this three these had fludarabine the a consists protocols changes a was pancytopenia, cyclophosphamide our cyclophosphamide, used We four days of lymphodepletion for in lower

the these and the changes. frequently to have Drug and queries, We responding communicating have with trials Administration, Food continued with been

completing dose presentation cells trial, without which trials our into one three made of clearer oral have past trial making conferences cell updated hepatocellular Of more an with initiating escalation as sarcoma be the at of billion occurring across the evidence new and later fall. progress plan We month. within updates is at the the ADP-AXMXX ADP-AXMX throughout AFP last evidence data clinical evolve. also and We tumors. trials, great year, the from this hepatotoxicity at ADP-AXMX We're will progress at give trafficking to data medical note, our with ESMO

at working coming It has improved working On in would progresses current with turn been a and personal to look the and Adaptimmune to thank Adaptimmune, now those especially a seeing like great R&D. note, to products over the I call Ad. years. the my and you, And colleagues months I will I Ad? how forward all here experience

Adrian Rawcliffe

Rafael. Thanks,

built at having in We'll company to take years. with has to a pivotal active done on he and our be well in pipeline. our and trials coming Adaptimmune, lead capabilities commercial aim rapid product XXXX. our moment commercial existing want excited product and current am as months, for the beyond last for focusing as We the building and Adaptimmune this to expertise of of opportunity XX very a execution, I to to field we've the the weeks forward everything enable the James the launch delivery leveraging for once are I move integrated for thank again over

with And questions. for the open call Operator? turn that, I'll

Operator

from question SunTrust [Operator is Lawson ahead Peter instructions] Go Robinson please. Humphrey. Our of first

Waleed Abdel-Naby

protocol provide color that Could a and Peter is guys. Thanks on ADP-AXMXX Lawson. changes for made to the the Waleed please This the for you for Hi, more trials? bit just ADP-AXMX taking my was questions. on

Adrian Rawcliffe

Rafael? Certainly.

Rafael Amado

Yes.

the lined So that conditioning regimen immediately, the up changed after this patients for event, for we treatment. were

We've XXX the all using. MXX now protocol, to fludarabine and the MX which has for three, times cyclophosphamide, have per criteria. that meter made cyclophosphamide the a our we previous milligrams has now which been square dose the the XXX So have with incorporated dose of protocols dose except same. lower AFP inclusion milligrams been square changes per much per all we That anyway. lowered per remaining our xX But day protocols some into is to day meter

doing continued relate complement been in enter the these the with already. cerebrovascular because the history marrow disease. study. to FDA clearance, have we're creatinine as we and into have a discussion And now type changes. age we've having patients with the any have excluding And these bone changes of before, of are of stroke, We've to said some that patients done experiments maximum to studies. all So also have the for to studies in some amendments preclinical study. that the a And entry There are made we've put also been any better function I

Waleed Abdel-Naby

Great. That's the synovial expect be little expected clinical How ESMO. we updates sarcoma? bit different it previous a in just the at update to upcoming really more in from will on And see data? the can What helpful.

Rafael Amado

pattern wait simply have say the majority I them the the actually, really tumor patients MRCLS, that synovial to continued results. accrual of it been treat just our that we but be. to I sarcomoa. of Well, qualitatively patients. has treated Obviously, have with different can't would see we shrinkage continues. robust. how some say say I And We've can will quite will

Operator

from Securities. is question Michael Schmidt of Go the Next Guggenheim ahead from please. line

Kelsey Goodwin

is Hey, guys. for Kelsey on Michael. This

just confidence there's gives terms of a what a CAR-T. whole of been kind bit TCR we're I especially progress of -- little wondering category, the we're guess, little guess, in think kind we're you I for disappointment TCRs investors using the among light gears from I -- different plans compared to perhaps any bit shared combination? is there putting the sort that maybe, is in to antigens several shift Thanks. some there And the target more to them tunnel? and little at neoantigens that of antigens end of a of or

Adrian Rawcliffe

Yes.

I give that developable that the underline any which, to sarcoma, we to that radiation one can certain think, although initiating comment think to patients for I under SURPASS TCR But benefit with path think data field. to in does targeted effective just May the that a tumors response indications, that have which on approaches we second-gen the is forward was of products. circumstances And clearly tumor study, solid us SPEARHEAD-X in the So across showed regard the and data we as derive the saw medicines that trial, T-cells has those progress underscores basis the us the types, activity TCR started. are to that enable outlined that and sub-study insufficient I forward then that against understand confidence and just the the secondly, that real be us there into we've

So that's focus. our I think

a just that think as to to date, and out platform branch that also the that beyond the platform broad of of to Now talked us think and I'll a well if mention doing platform about our the looks at our I basis real the at I that's refer already the that first you like I allogeneic T-cell TCR capabilities comments did willingness prime we that you forward. goes therapies. we've pipeline our think, T-cell world embrace that, what that beyond, we're go to the a things company, to the things cell during about therapy is platform obviously seat at my give And we built SPEAR as like and ASGCT table look

company, and therapy cell in we have opportunity a as think we product, I pipeline, this So go have the to and that's we're a have time. saying beyond we all at a point that,

Kelsey Goodwin

I guess, I NY-ESO, And helpful. then was I terms kind guess, in top? of synovial synovial if one really be kind also the NY-ESO? sarcoma of you that's sarcoma that's to making more, how both clustered of is That of and see just across then you think kind versus it Thanks. MAGE-AX do great. one what MAGE-AX being of the the And Okay, can. do responses the rising in positioning

Rafael Amado

question The Rafael. susceptible to TCR, one ourselves is this wonder why of that tumor So this obviously, we too. it's is

is this which are rather. hardly or expressed the immunogenic. There tumor every antigens triggers a very result diffusely think neoantigens generally poorly translocation, at the of in I It's They're expression this antigens. cancer/testis level. generally high a that's cell and of any

is target is it the much more than in So tumors. abundant other

of may the factors. one So that be

is essentially suppressive are again devoid is of because other The the tumors inflamed, element. tumor the not microenvironment

tumors tend cytotoxicity very any, TILs very these as don't to unimpeded. so they antitumor may are the if activity. know, T-cells inhibitors opportunity that exert And work cause traffic and in checkpoint you because really can well few, And have to

So I the tumors expression more combination it's sarcoma microenvironment makes is, density going a make a forward. how improvements ideal and question we more together a probably environment, to and like TCRs do think target technology. favorable And this synovial sarcoma of for making epithelial that MRCLS with

Operator

from next Cowen. the question is Frahm line Our from ahead, Marc please. of Go

Marc Frahm

Hey. my the neurotoxicity on that detail timing confident Thanks to of related And you Rafael, give that them? why more wasn't a questions. in of neurotoxicity? you're little for seen the stroke? was stroke kind can just the And the bit taking

Rafael Amado

had she commands, exam stroke, of and then She family first the neurotox found atrial worsened, cerebrovascular patient with other cancer, with steroids. confusion, manifested her approximately CT who developed neurologic agent multiple following cetera. have It she accident, by So -- a scans physical showed no -- week a edema, a so woman. infusion. of evidence anti-IL-X scan for she And after developed was ischemic ovarian evidence and not mostly of And and multifocal fibrillation. a agents She opted to was She was care. was showed including et had CAT a XX-year-old is morbidities that had and patient exam then she on that treated this cerebral areas. with hospice

consistent edema. they are of events neurotoxicity, with neurotox think some but distinct that series we were So two that the scans there no CAT during a just showed changes

multiple was And her physical worsened on different infarcts. then very when exam, she scan CAT again showing

multifocal any So can't was atrial watershed this for patient. of can clinical that fibrillation there the what cause the she -- evolution cause but But obviously, patients which infarcts, to that's had, predispose is was for the tell we other stroke. that sure whether was or

Marc Frahm

was data were within regimen many in that this using And here from? mean, subset cyclophosphamide, of back given But patients that the lower the us you've a What you then regimen of us maybe switching treated how patients? conditioning escalation moving dose dose kind the I remind the that can times about thinking response few the a to remind in forward, the -- just you changed of cohort just using can rate you're period.

Rafael Amado

patients Actually, XXX in per on the Yes. xX. that of majority we with milligrams May meter the were reported treated

So I treated treating patients started couple May, think we only a X,XXX and milligrams. we after at of

regimen with And X,XXX regimen first of activity the study it four with events. that past, dose NY-ESO chemotherapy high-dose again trial, NCI fludarabine pancytopenic didn't was tolerated. the as so a of had preparative the cyclophosphamide. milligrams the was any really the and fatal And chemotherapy And In cohort, with at report in they was the the lower again, days a well regimen. in done time

gamma-chain given to safety that the had try we And lymphodepletion. before, with secretion data IL-XX IL-X we cytokines depth observed increase to, the T-cell, had and increase that wanted of to our maximize we So proliferation.

And to that's milligrams. so X,XXX why we increased

of So well. we that positive the it's the question data reverted with is have regimen the to, And to and recovered that answer we we've benefit-risk safer. believe have patients

with commentary, two pancytopenia lung end to the I had the to patient patient transplants. had first that And just the referred cancer,

decision with of a but him cyclophosphamide did The a he retreat And didn't to had and a marrow recover. dose of was well. the attain partial recovered higher dose lymphodepletion, fairly and almost response. partial response, the first was he with lower He his

we again we that's are proceeding. how milligrams think safe have that I and So evidence XXX is

Marc Frahm

the there marrow talking the sarcoma Do but that got response, person partial the didn't a about is you're that that lung that the or cancer? was to recover, patient

Rafael Amado

The lung cancer patient.

Operator

Our next please. question Bansal Mohit ahead is from Citi. Go from

Keith Tapper

for Keith on Hi, guys. is This Mohit.

allogeneic but to I want timing if or my the then program, could future improve, long-term are I secondly, at you questions to protocol the see know of once answered, are the manufacturing think significantly? the the it you going as to data lot this access changes And on impact Or a just autologous are replacing option? the for developing studies? however, looking a and

Adrian Rawcliffe

of the on recruitment, significant don't trials on we impact So based on recruitment anticipate timing the the the changes. of

you've attractive exciting. that in we our program development product opportunities allogeneic do It think into further programs, but for this among most we've represents is is study allogeneic seen we pipeline. the The with profile And advanced because product project, known mentioned very product both we've SPEARHEAD-X have the feel actually look responses us. trial the there. talked we first-generation an with On to of most allogeneic think and homogenous to product the organization, we behind, what and with as further and I for longer-term I off is advanced product. will world as is is a the convert the the exactly therefore, but And obviously fairly focus an -- not to the programs, of product stem those it's opportunity about option, of the allogeneic cell-derived think the autologous also activity and the development shelf autologous the of fairly, like before, relative a said, are

Operator

Our Go is SVB Chang please. next question of ahead from Leerink. Jonathan

Jonathan Chang

Hi, guys. Thanks questions. for taking my

patient more treatment-related, provide talk that lymphodepletion you can that the regimen for that were on moving confidence issue deemed and will reasons avoid question, your forward? First to this suffice changes to deaths color about the

Adrian Rawcliffe

that believe, is, is the treatment then not to second ask the And related, to -- went treatment. deal clearly we pancytopenia, Rafael related. cyclophosphamide the pretty do to we piece I'll the to but with is Jon. not sort Thanks, that's maybe on And But Rafael that. related is we stroke think obviously, the point, the dosing. think, of just say as T-cell that through, that -- related

to Rafael, So on do you that? want comment further

Rafael Amado

this No. said I older with think patient and that patients we relatively sarcoma, another one the was mean, I've the I before. -- than other two These patient were treat. average had that's to that ovarian was because physician received could and and prior patient progressing And the lung. epithelial felt he and wait. had the conditioning not tumors, sarcoma cyclophosphamide high-dose she There

And so she received the right high-dose cyclophosphamide, after conditioning. then

The with lymphodepletion. fact have been before that So a right had she may that very regimen well. as myelosuppressive contributed treated

second And the as in seven mentioned transplants two I patient, months. the before, span had of

think We And as carefully. transplant chemotherapy. cases at committee is all due cases bone marrow review really the well. have added very this scientific these that obviously we to a we review looked that to experts So some in

to up get do And pancytopenia. shown XXX we have conclusion. evidence had no of cohort the prolonged recover. And was sarcoma that MXX, where by the we cohort the was the expansion previous cytopenias, of and but milligrams lower from they previous that data MX and backed Patients to recommendation

data on say can based that's we So have. I the what

Jonathan Chang

the one year then And update presentation at the from beyond we ESMO? expect sarcoma Should synovial more AX later question. an AXX just studies MAGE-AX, this

Adrian Rawcliffe

-- as are study. about, AXX talked we closing we the are So we

reasonable may when the communicate. it year. be happen in we have will on may to not to I this remainder think data study, the we able but update It happen of AX

Operator

from Birchenough instructions] from ahead question please. Fargo. [Operator is Our Go next Jim Wells

Jim Birchenough

Thanks for the on the detail studies.

creatinine and you of bone on you have patient Just exclusion much marrow addressable other you inclusion consider the looked how levels a age, What shrink question By that? some market, these the reserve, in amended protocol. at exclude does does addressable ultimate clearance on when that population have the certain criteria when factors? that impact your

Rafael Amado

individually. patients. younger one Obviously, is sarcoma looked We've at a disease each of

are sarcoma. have their few there very So that XXs patients in synovial

permissive would marrow much strengthened, inclusion So study. a the I fludarabine. of although I same the think of they of with what it there's the label creatinine comment realm a reflect that's not factors, dose to the criteria. really factor. we suggest fairly a because The just make you would just clearance, of I still see doesn't product in the are before want And of within criteria, that And Phase was bone the rest necessarily

gets all the I changes relatively the selected. all. oftentimes details at were if overall, indication significantly that would are selection. product that recruitment rate patients how affect doubt It's be these So in But the of or approved, this won't independent the the minor

Jim Birchenough

FDA? you And to around the then, discussions and with understood just Rafael, modifications any protocol need has sure want in feedback formal make is your or those them? this additional there's on to by full I if the risk any I from dialogue FDA through further there this? Are agreement brought protocol comments that FDA with just to been modifications. Just the confident you still of Is assess want

Rafael Amado

early protocol. the with asking They and changes quickly. wanted very able Obviously, We were up fairly protocol came on, them, in changed fast. were of the obviously, most which acknowledging the to we to specific questions, our address communications discussions and see we

or our think come But ago. trials questions if communication we last with don't has the as been almost of three changes. know back weeks to other going Obviously, today, probably I is continue. FDA

longer. at little last a will set to that I take time the be as have, our I again But And I soon that TCRs, it's ago. bit was clinical look in will measures it marrow the precursors interaction as have we vitro we We outlined discussions, alluded as and effect FDA. some that undertake would to of but submitted the the ready, as will data bone said, think of before, in

their we So But you know. never satisfied like feel we now, queries. for

Jim Birchenough

It is topic. the the finally phenomenon like release pretty on cyclophosphamide, excluded you have T-cell-related this that direct effects on to through of confident cytokine but And T-cells? platelets, sounds it's effect the related sort SPEAR thrombocytopenia also a some whether then just of maybe you're or

Rafael Amado

Yes. The were cytopenias trilineage.

studies in So terms supposed do wasn't do. what question of role became of can transfusion-dependent. The so excellent was cells how cells, TCR. it the platelets, white is you that's these it a And just red the and patient in exclude cells in does bone marrow, vitro to may are have whole one overlooked precursors, bone in We stem obviously other been and marrow. by marrow intermediate if it which unfractionated it but

So doing of we seen this, we've it the has in tens done and NY-ESO are with more. been But past.

is, with before has said, anemia It patient MX. been patient sarcoma TILs, very treated seen and MXX was the has treated MXX, I which with Aplastic described. been with was as well lung that's cancer seen the with

So due T-cells the is have fact alkylators ruling completely patients that to of multiple conditioning, difficult occurs and prove culprit the in probably across that it effect out that the of modalities to it's even negative. because high thinking and you But response. than is the the that it's get other a immune doses occurs and it suggest conditioning an TCRs more the

Jim Birchenough

maybe just broader study. final and the question And then just SURPASS one on

neoantigen Just the there? synovial sarcoma or types? looking strategy, certain enhanced separately, see antigen at on more that activity just new AX if details what we tumor might next-gen in whether get you could goal if you is or then it's a comment family expectation your might a activity you're study, look wondering or Just And you there's what SURPASS if have might into in neoantigen see when one? When the data? on Thanks. we strategy, other wondering broader to

Rafael Amado

in CDX a together So, delivered the is terms is MX study same alpha. SURPASS, TCR of with so where this

to, as is the for coreceptor X this CDX TCR So intention a manipulation cells. Class to CDX provide of one,

express although cells so kill, can long term. persistent, when a don't CDX lower is they weak. you binding So they they obviously CDX rate disappear their at look do and essentially and at And

alpha So what cells we've CDX the they CDX molecule. well that kill as contain to when are cells CDX able just shown as is

will cytotoxic we effect, in of number increase so And the cells.

and a And in of -- CDX/CDX factors of That's starting bit CDX. ratio it sometimes, on other product. the it's among is the random just -- depends on favor

because could it way, the simplistically a transduced dose functional, all the cells in be higher functional. will So a all be would cells as be seen

helper expand, at In MHC they these they kill, least stabilize and importantly, are CDX shown Class which are to I and including addition, they interacting setting providing cells these able activated, dendritic deliver more of in activation, and because me, I dendritic cell of they we've cytokines think, bind with cells. for function, they their co-cultures cells increasing they the cells, and the and

all TCR, difficult That's vitro, positive. transduced I CDX this the antigenic spread. activity the alpha-bearing to should in to so And APCs but lead when next-generation of that are CDX of prove the it's think actually enhanced get with fact you cells quite

be more even spread CDXs engaged. And perhaps, So will are assays we will antigenic in potent think we're where will, maybe And measure to our and all going to get a more humoral patients. we there that immune developing response, response. you if of be

understand help there studies of us set So translational how to will be it works.

that I relate don't we announce can And program. that neoantigens, do them. ongoing think in we to programs due is terms the I all In but -- say And field. we've course, have next will this of disclosed

Adrian Rawcliffe

the And then about data to just half first just first the asked you in up data we've lastly, the XXXX. anticipating we're SURPASS and of pick from confirmed the on, when study, would first be,

Operator

Capital Tony next Our question Roth Partners. is from ahead Butler Go please. from

Tony Butler

Thanks questions. Yes. much. Two Good morning. very

this. XX got on bit But you on et announced you this effects, and the associated cyclophosphamide and if you we morning, around you've I futility First, first my if had and late. But go out when a patients. challenges, interim mentioned the apologies of obviously, on. recognize of announced responses when a and -- three with questions Adrian, analysis I it's the side lot SPEARHEAD, cetera, and can

say true how will passed in do we additional just question the to That's intrigued give would you futility always additional you what the radiation is, two, I that? those opportunities -- you first T-cell question clearly MD The Rafael, really create by incremental the or trial. analysis one. And question around Will XX some Anderson for information patients? It's then notion am penetration.

I been I do through giving today. the just just a a lymphodepletion, undergo lymphodepletion grays I appreciate little subsequent same recognize would correct? discussing then to a then it's which So they you're very we've trial. And that And bit am seven interesting assuming get patient. outlining Is go ramp? that they cells. you because is They then

Adrian Rawcliffe

Tony. Thanks,

you response So patients XX critical the might -- three we've patients. just the Clearly, that The first and would something occur in to dosed given patients rate. one, the is three give responses date, than anticipating a on up to than seen responses pick like fewer obviously are the XX we less XX% something rate piece. that of

product. hopefully the trial, is this of at be will And to -- just talk question, completed to a that acknowledging at in using but sub-study? will and we we to the the have do that the the as you next you're Rafael, giving that opposed announce progresses radiation some right, we register study analysis use likely -- data, which we point time, are any point want about further

Rafael Amado

Yes, sure.

lesions days. the low-dose during lymphodepletion will the radiotherapy receive patient So to selected

checkpoint that which being trafficking to there's seven inhibitors differential various there's will, the our they selected see checkpoint based responsiveness also idea mentioned, of will can and be to are to there radiation to sublethal and the showing restore group response by go this all and animal from suite CARs how the is discretion in that at on of whether world and And And the very lesions differential won't. actually CARs literature. will the be be radiation So Memorial were selected in that increased observations documented And the somewhat metastases. T-cells Not the whether grays between four is same dose oncologist. will days that also It's you is radiated, low-dose given well from and will irradiated. of to them actually was model essentially some patients a refractory the get a using published is lymphodepletion radiation lesions. the cytotoxicity the phenomenon over lesions with lesions as

pretty we're this about So study. excited

sub-study it a it's how data, could that the we gave help we us the information TCRs opportunity also translational us work. to -- but should the will fact learn responses, also us build think it open, as I and of with exciting -- is that launching it pretty seems which quickly. already and both get with for And

Operator

now to call And Thank Adrian back I you. to Rawcliffe. the over turn Adrian? like would

Adrian Rawcliffe

and T-cells thanks Thank you as Thank updating to And with and with you, support call. our the that, SPEAR continued progress everyone close cancer. interest to we bring patients we'll look company. the forward for to your We forward you. of

Operator

Call. all concludes This attending. for Conference today's Thank you

disconnect. now may You

Adaptimmune Therapeutics (ADAP) 3 Aug 192019 Q2 Earnings call transcript